Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.74 USD | -3.11% | -11.52% | -16.46% |
Apr. 04 | Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing | MT |
Apr. 04 | Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing | MT |
Evolution of the average Target Price on Beam Therapeutics Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Beam Therapeutics Inc.
Barclays | |
RBC Capital Markets | |
Wedbush | |
JPMorgan Chase | |
BofA Securities | |
Jefferies & Co. | |
Cantor Fitzgerald | |
Credit Suisse | |
Citigroup | |
Bernstein | |
Wells Fargo Securities | |
SVB Securities LLC | |
BMO Capital | |
Guggenheim | |
SVB Leerink | |
Redburn | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- BEAM Stock
- Consensus Beam Therapeutics Inc.